Loading
A phase 1 trial of Afuresertib run by Laekna Limited, completed.
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC is a phase 1 interventional study registered as NCT05390710 by Laekna Limited, with 21 participants enrolled, started 2021-06-12, primary completion reached 2023-12-11. Conditions recorded: Solid Tumor, TNBC - Triple-Negative Breast Cancer. Interventions recorded: LAE005 + Afuresertib + Nab-Paclitaxel.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/